Asia-Pacific and Middle East Medical Implants Market

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. PORTER’S FIVE FORCES ANALYSIS
3.4. TOP PLAYER POSITIONING
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

CHAPTER 4 ASIA-PACIFIC AND MIDDLE EAST MEDICAL IMPLANTS MARKET, BY PRODUCT

4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. ORTHOPEDIC IMPLANTS
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast
4.2.3. Reconstructive Joint Replacements
4.2.3.1. Market size and forecast
4.2.3.2. Knee Replacement Implants
4.2.3.2.1. Market size and forecast
4.2.3.3. Hip Replacement Implants
4.2.3.3.1. Market size and forecast
4.2.3.4. Extremities
4.2.3.4.1. Market size and forecast
4.2.3.5. Orthobiologics
4.2.3.5.1. Market size and forecast
4.2.3.6. Trauma & Craniomaxillofacial
4.2.3.6.1. Market size and forecast
4.3. CARDIOVASCULAR IMPLANTS
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast
4.3.3. Pacing Devices
4.3.3.1. Market size and forecast
4.3.3.2. Cardiac Resynchronization Therapy Devices (CRTs)
4.3.3.2.1. Market size and forecast
4.3.3.2.2. CRT-P (CRT with pacemaker function)
4.3.3.2.3. Market size and forecast
4.3.3.2.4. CRT-D (CRT with pacemaker and ICD function)
4.3.3.2.5. Market size and forecast
4.3.3.3. Implantable Cardioverter Defibrillators (ICDs)
4.3.3.3.1. Market size and forecast
4.3.3.3.2. Transvenous Implantable Cardioverter Defibrillator (T-ICDs)
4.3.3.3.3. Market size and forecast
4.3.3.3.4. Subcutaneous Implantable Cardioverter Defibrillator (S-ICDs)
4.3.3.3.5. Market size and forecast
4.3.3.3.6. Implantable Cardiac Pacemakers (ICPS)
4.3.3.3.7. Market size and forecast
4.3.4. Stents
4.3.4.1. Market size and forecast
4.3.4.2. Coronary stents
4.3.4.2.1. Market size and forecast
4.3.4.2.2. Drug-eluting Stents (DES)
4.3.4.2.3. Market size and forecast
4.3.4.2.4. Bare-metal Coronary Stents
4.3.4.2.5. Market size and forecast
4.3.4.2.6. Bioabsorbable Stents
4.3.4.2.7. Market size and forecast
4.3.4.3. Peripheral stents
4.3.4.3.1. Market size and forecast
4.3.4.3.2. Iliac
4.3.4.3.3. Market size and forecast
4.3.4.3.4. Femoral-Popliteal
4.3.4.3.5. Market size and forecast
4.3.4.3.6. Renal
4.3.4.3.7. Market size and forecast
4.3.4.3.8. Carotid
4.3.4.3.9. Market size and forecast
4.3.4.4. Stent related implants
4.3.4.4.1. Market size and forecast
4.3.4.4.2. Synthetic grafts
4.3.4.4.3. Market size and forecast
4.3.4.4.4. Vena cava filters
4.3.4.4.5. Market size and forecast
4.3.5. Structural Cardiac Implants
4.3.5.1. Market size and forecast
4.3.5.2. Mechanical Heart Valves
4.3.5.2.1. Market size and forecast
4.3.5.3. Implantable Ventricular-Assist Devices
4.3.5.3.1. Market size and forecast
4.3.5.3.2. Left Ventricular Assist Device (LVAD)
4.3.5.3.3. Market size and forecast
4.3.5.3.4. Right Ventricular Assist Device (RVAD)
4.3.5.3.5. Market size and forecast
4.3.5.3.6. Biventricular Assist Device (BIVAD)
4.3.5.3.7. Market size and forecast
4.4. SPINAL IMPLANTS
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast
4.4.3. Interbody Fusion Devices
4.4.3.1. Market size and forecast
4.4.4. Thoracolumbar Devices
4.4.4.1. Market size and forecast
4.4.5. Cervical Fixation Devices
4.4.5.1. Market size and forecast
4.4.6. Spinal Electrical Stimulation
4.4.6.1. Market size and forecast
4.4.7. Vertebral Compression Fracture (VCF) Devices
4.4.7.1. Market size and forecast
4.4.8. Motion Preservation Devices
4.4.8.1. Market size and forecast
4.5. NEUROSTIMULATORS
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast
4.5.3. Deep Brain Stimulation (DBS)
4.5.3.1. Market size and forecast
4.5.4. Sacral Nerve Stimulation (SNS)
4.5.4.1. Market size and forecast
4.5.5. Vagus Nerve Stimulation (VNS)
4.5.5.1. Market size and forecast
4.5.6. Other neurostimulators
4.5.6.1. Market size and forecast
4.6. OPHTHALMIC IMPLANTS
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast
4.6.3. Intraocular Lens
4.6.3.1. Market size and forecast
4.6.4. Glaucoma Implants
4.6.4.1. Market size and forecast
4.7. DENTAL IMPLANTS
4.7.1. Key market trends, growth factors and opportunities
4.7.2. Market size and forecast
4.7.3. Plate Form Dental Implants
4.7.3.1. Market size and forecast
4.7.4. Root Form Dental Implants
4.7.4.1. Market size and forecast
4.8. BREAST IMPLANTS
4.8.1. Key market trends, growth factors and opportunities
4.8.2. Market size and forecast
4.9. FACIAL IMPLANTS
4.9.1. Key market trends, growth factors and opportunities
4.9.2. Market size and forecast

CHAPTER 5 ASIA-PACIFIC AND MIDDLE EAST MEDICAL IMPLANTS MARKET, BY BIOMATERIAL

5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. METALLIC BIOMATERIAL
5.2.1. Market size and forecast
5.3. CERAMIC BIOMATERIAL
5.3.1. Market size and forecast
5.4. POLYMERS BIOMATERIAL
5.4.1. Market size and forecast
5.5. NATURAL BIOMATERIAL
5.5.1. Market size and forecast

CHAPTER 6 ASIA AND MIDDLE EAST MEDICAL IMPLANTS MARKET, BY REGION

6.1. OVERVIEW
6.2. ASIA-PACIFIC
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast
6.2.3. Japan medical implants market
6.2.4. China medical implants market
6.2.5. India medical implant market
6.2.6. Rest of Asia-Pacific medical implants market
6.3. MIDDLE EAST
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast
6.3.3. UAE medical implants market
6.3.4. Saudi Arabia medical implants market
6.3.5. Israel medical implants market
6.3.6. Rest of Middle East medical implants market

CHAPTER 7 COMPANY PROFILES

7.1. ABBOTT LABORATORIES
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. BIOTRONIK SE & CO. KG
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. BOSTON SCIENTIFIC CORPORATION
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. C. R. BARD, INC.
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. CARDINAL HEALTH, INC.
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. CONMED CORPORATION
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. GLOBUS MEDICAL, INC.
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. JOHNSON & JOHNSON
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. LIVANOVA PLC
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. MEDTRONIC PLC
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments